Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), increasingly utilized for the management of DM and obesity, effectively lower blood sugar and reduce hunger [14,15] by stimulating insulin secretion, suppressing glucagon secretion, and delaying gastric emptying [7,16]. This evidence concerns the gene GLP1R and Obesity.